Page 6 of 11
PE2.3 | Short Stature — Summary & Reflection
KEY TAKEAWAYS
Key takeaways from this module:
- Short stature = height-for-age < −2 SD; severe = < −3 SD. Growth velocity (<4 cm/yr prepubertal) is more important than a single measurement.
- Normal variants (FSS + CDGP) account for the majority of referred cases and require reassurance, not treatment. Distinguish by bone age (FSS = normal; CDGP = delayed) and family history.
- Pathological causes: endocrine (GHD, hypothyroidism, Cushing's), systemic (coeliac, CKD, CHD, HIV, TB), nutritional (PEM, zinc deficiency), skeletal dysplasia, chromosomal (Turner, Down, Noonan).
- Assessment sequence: growth chart (height + velocity) → MPH calculation → bone age → body proportions → targeted history/examination → investigations by clinical pattern.
- Key investigations: TSH/fT4, IGF-1, anti-tTG IgA (coeliac screen), karyotype (all girls with unexplained short stature), GH stimulation test (if GHD suspected), MRI pituitary.
- Treatment is cause-specific: rhGH 0.025–0.035 mg/kg/day SC for GHD; levothyroxine (weight-based) for hypothyroidism; nutritional rehabilitation + zinc for nutritional; Turner = high-dose rhGH + oestrogen.
- Always ask about exogenous steroid use — a missed cause of iatrogenic short stature.
REFLECT
Return to the opening case — the 10-year-old boy with height −2.5 SD, growth velocity 4.2 cm/yr, bone age 8 years, normal IGF-1, and a father who was a 'late bloomer.'
- Having worked through this module, what is your diagnosis and what is the single most important message to communicate to this family today?
- At what point would you consider a follow-up visit essential, and what specific measurement would trigger a reassessment of your diagnosis?
- This module framed short stature as requiring a 'cost-effective' approach rather than a blanket investigation panel. Reflect on how you will decide, in practice, when to investigate and when to reassure. What clinical features would shift your threshold?
- A colleague argues that every short child should receive rhGH to 'maximise their potential.' How would you respond, drawing on this module's evidence base?